New Enterprise Associates, a venture capital firm, led a $70m series C round in Inversago Pharma, a clinical stage biotech company, with participation from Forbion, Amgen, Fonds de solidarité FTQ, Genesys Capital, AmorChem, JDRF T1D Fund and adMare BioInnovations. “We are privileged to have the support and commitment of such an impressive investor syndicate at this critical stage of the Company’s development. This new round of financing is a strong endorsement of the whole Inversago team, who have carried the vision to leverage the potential of the CB1 blockade in developing potent treatments for a growing number of patients suffering from metabolic conditions, such as Diabetic Kidney Diseases and other diabetes-related condition,” François Ravenelle, Inversago Pharma CEO.